Extraterrestrial opportunities will be the focus of the 21st century, driving scientific studies and paving the way for future space  settlement. One of the challenges humans must overcome to realize this  ambition is the loss of bone and muscle mass caused by prolonged stays in  microgravity (six months or longer). Amorphical manufactures a form of calcium called “amorphous calcium  carbonate” (ACC), demonstrated by clinical and paraclinical studies to have  significantly higher absorption rates that lead to a bigger increase in bone  and muscle mass relative to other solutions.  

The experiment was conducted by SpacePharma — a biotech company  specializing in conducting experiments in microgravity — using their  lab-on-a-chip technology. During the experiment, human muscle and bone cells  were exposed to media containing amorphous calcium carbonate (ACC), while  control cells were not. The researchers then examined the cells’  differentiation with and without amorphous calcium carbonate.  This was a follow-up experiment to a previous one conducted through the Ramon Foundation’s Spacelab Project five years ago on mouse bone cells.

Read the scientific paper

‍